| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 15 | 2022 | 18 | 4.930 |
Why?
|
| Brain Neoplasms | 14 | 2022 | 297 | 3.990 |
Why?
|
| Radiosurgery | 9 | 2021 | 82 | 3.230 |
Why?
|
| Meningeal Neoplasms | 6 | 2021 | 73 | 3.030 |
Why?
|
| Meningioma | 6 | 2018 | 79 | 2.440 |
Why?
|
| Publications | 4 | 2018 | 24 | 2.280 |
Why?
|
| Internship and Residency | 7 | 2021 | 228 | 2.270 |
Why?
|
| Radiotherapy | 6 | 2021 | 39 | 1.970 |
Why?
|
| Career Choice | 5 | 2020 | 52 | 1.850 |
Why?
|
| Neurosurgical Procedures | 5 | 2021 | 215 | 1.830 |
Why?
|
| Medical Oncology | 4 | 2025 | 87 | 1.620 |
Why?
|
| Humans | 80 | 2025 | 27169 | 1.470 |
Why?
|
| Radiation Oncologists | 7 | 2020 | 7 | 1.360 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2020 | 160 | 1.290 |
Why?
|
| Lung Neoplasms | 8 | 2020 | 342 | 1.250 |
Why?
|
| United States | 18 | 2025 | 2070 | 1.140 |
Why?
|
| African Americans | 3 | 2018 | 350 | 1.090 |
Why?
|
| Databases, Factual | 4 | 2021 | 251 | 1.080 |
Why?
|
| Neuroma, Acoustic | 2 | 2017 | 23 | 1.080 |
Why?
|
| Glioblastoma | 4 | 2020 | 101 | 0.990 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 312 | 0.990 |
Why?
|
| Male | 33 | 2025 | 13040 | 0.970 |
Why?
|
| Combined Modality Therapy | 10 | 2022 | 291 | 0.930 |
Why?
|
| Private Practice | 4 | 2021 | 8 | 0.920 |
Why?
|
| Bibliometrics | 3 | 2018 | 19 | 0.880 |
Why?
|
| Muscle Proteins | 2 | 2015 | 55 | 0.870 |
Why?
|
| Aged | 19 | 2021 | 5234 | 0.870 |
Why?
|
| Female | 32 | 2025 | 14662 | 0.850 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2021 | 35 | 0.820 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 151 | 0.820 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 375 | 0.810 |
Why?
|
| Melanoma | 2 | 2021 | 128 | 0.800 |
Why?
|
| Authorship | 2 | 2018 | 13 | 0.750 |
Why?
|
| Peer Review, Research | 2 | 2018 | 8 | 0.740 |
Why?
|
| Spinal Neoplasms | 2 | 2020 | 39 | 0.720 |
Why?
|
| Astrocytoma | 1 | 2021 | 34 | 0.720 |
Why?
|
| Prostatic Neoplasms | 4 | 2017 | 271 | 0.720 |
Why?
|
| Autophagy | 4 | 2009 | 72 | 0.710 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 103 | 0.710 |
Why?
|
| Glioma | 1 | 2022 | 117 | 0.710 |
Why?
|
| Lymphoma | 1 | 2020 | 22 | 0.710 |
Why?
|
| Middle Aged | 21 | 2021 | 6913 | 0.700 |
Why?
|
| Whole-Body Irradiation | 1 | 2020 | 38 | 0.700 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 103 | 0.680 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 117 | 0.680 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 242 | 0.680 |
Why?
|
| Students, Medical | 2 | 2018 | 94 | 0.680 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 88 | 0.680 |
Why?
|
| Germinoma | 1 | 2019 | 4 | 0.650 |
Why?
|
| Neoplasms | 5 | 2021 | 768 | 0.650 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 12 | 0.650 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2010 | 537 | 0.620 |
Why?
|
| Health Policy | 1 | 2019 | 60 | 0.620 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2018 | 1 | 0.610 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 288 | 0.610 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2018 | 4 | 0.610 |
Why?
|
| Wireless Technology | 1 | 2018 | 2 | 0.610 |
Why?
|
| Apoptosis | 7 | 2015 | 740 | 0.610 |
Why?
|
| Magnetic Field Therapy | 1 | 2018 | 3 | 0.600 |
Why?
|
| Financing, Personal | 1 | 2018 | 4 | 0.600 |
Why?
|
| Cell Phone | 1 | 2018 | 19 | 0.600 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2018 | 60 | 0.600 |
Why?
|
| Patient Safety | 1 | 2018 | 36 | 0.600 |
Why?
|
| Lymphocytes | 1 | 2018 | 82 | 0.580 |
Why?
|
| Neurosurgery | 4 | 2021 | 75 | 0.580 |
Why?
|
| Receptor, trkB | 4 | 2012 | 6 | 0.570 |
Why?
|
| Retrospective Studies | 12 | 2022 | 2453 | 0.570 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2017 | 1 | 0.570 |
Why?
|
| Essential Tremor | 1 | 2017 | 2 | 0.570 |
Why?
|
| Spinal Cord Compression | 1 | 2017 | 20 | 0.570 |
Why?
|
| Deep Brain Stimulation | 1 | 2017 | 7 | 0.560 |
Why?
|
| Ambulatory Care | 1 | 2017 | 58 | 0.550 |
Why?
|
| Insurance Coverage | 1 | 2017 | 31 | 0.540 |
Why?
|
| Efficiency | 5 | 2021 | 17 | 0.540 |
Why?
|
| Medulloblastoma | 1 | 2016 | 18 | 0.540 |
Why?
|
| Prognosis | 7 | 2021 | 763 | 0.530 |
Why?
|
| Palliative Care | 1 | 2017 | 79 | 0.520 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 989 | 0.510 |
Why?
|
| Neuroblastoma | 4 | 2005 | 56 | 0.500 |
Why?
|
| Adult | 12 | 2021 | 7506 | 0.500 |
Why?
|
| Stroke | 1 | 2018 | 241 | 0.470 |
Why?
|
| Brain-Derived Neurotrophic Factor | 3 | 2005 | 22 | 0.470 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 99 | 0.460 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2020 | 13 | 0.460 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 811 | 0.440 |
Why?
|
| Child | 6 | 2021 | 2159 | 0.400 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 144 | 0.400 |
Why?
|
| Treatment Outcome | 6 | 2020 | 2286 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 42 | 0.390 |
Why?
|
| Cell Line, Tumor | 9 | 2018 | 1271 | 0.380 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 448 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 189 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2012 | 446 | 0.370 |
Why?
|
| Protein Kinases | 3 | 2012 | 147 | 0.350 |
Why?
|
| Enzyme Inhibitors | 4 | 2013 | 247 | 0.350 |
Why?
|
| Central Nervous System Diseases | 2 | 2021 | 12 | 0.340 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2010 | 13 | 0.340 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2021 | 24 | 0.340 |
Why?
|
| Ferrosoferric Oxide | 2 | 2020 | 4 | 0.330 |
Why?
|
| Surveys and Questionnaires | 8 | 2025 | 935 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2009 | 9 | 0.320 |
Why?
|
| Survival Rate | 4 | 2021 | 411 | 0.320 |
Why?
|
| Radiation | 1 | 2009 | 3 | 0.310 |
Why?
|
| Molecular Biology | 1 | 2009 | 16 | 0.310 |
Why?
|
| Chemoradiotherapy | 2 | 2019 | 43 | 0.300 |
Why?
|
| Seminoma | 2 | 2018 | 2 | 0.300 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2020 | 35 | 0.300 |
Why?
|
| Testicular Neoplasms | 2 | 2018 | 15 | 0.290 |
Why?
|
| Radiotherapy Dosage | 4 | 2023 | 102 | 0.290 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 38 | 0.290 |
Why?
|
| Watchful Waiting | 2 | 2018 | 18 | 0.290 |
Why?
|
| Signal Transduction | 6 | 2013 | 1379 | 0.290 |
Why?
|
| Sirolimus | 2 | 2008 | 69 | 0.290 |
Why?
|
| Child, Preschool | 3 | 2021 | 1103 | 0.280 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 217 | 0.260 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 217 | 0.260 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2020 | 64 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2005 | 133 | 0.260 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 158 | 0.250 |
Why?
|
| Immunoblotting | 3 | 2015 | 123 | 0.240 |
Why?
|
| Cisplatin | 2 | 2003 | 175 | 0.240 |
Why?
|
| Carboplatin | 3 | 2019 | 107 | 0.230 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 225 | 0.230 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2025 | 36 | 0.230 |
Why?
|
| Hybrid Cells | 2 | 2021 | 8 | 0.230 |
Why?
|
| Cell Movement | 3 | 2015 | 353 | 0.220 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 462 | 0.210 |
Why?
|
| Animals | 12 | 2025 | 10093 | 0.210 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2002 | 26 | 0.200 |
Why?
|
| Benzamides | 1 | 2002 | 33 | 0.200 |
Why?
|
| Radiology | 1 | 2022 | 20 | 0.200 |
Why?
|
| Cell Proliferation | 3 | 2015 | 775 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 155 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2013 | 32 | 0.190 |
Why?
|
| Pyridines | 1 | 2002 | 102 | 0.190 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 75 | 0.190 |
Why?
|
| Antineoplastic Agents | 3 | 2009 | 660 | 0.180 |
Why?
|
| Tumor Burden | 2 | 2019 | 108 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 98 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 108 | 0.180 |
Why?
|
| Peer Review | 1 | 2020 | 14 | 0.180 |
Why?
|
| Prevalence | 2 | 2020 | 478 | 0.180 |
Why?
|
| Population Surveillance | 2 | 2018 | 85 | 0.180 |
Why?
|
| Societies, Medical | 1 | 2021 | 89 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 247 | 0.170 |
Why?
|
| Radiotherapy, Conformal | 1 | 2020 | 15 | 0.170 |
Why?
|
| Cell Cycle | 3 | 2012 | 155 | 0.170 |
Why?
|
| Ependymoma | 1 | 2020 | 11 | 0.170 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2019 | 3 | 0.160 |
Why?
|
| Carcinoma, Large Cell | 1 | 2019 | 6 | 0.160 |
Why?
|
| Financing, Government | 1 | 2019 | 7 | 0.160 |
Why?
|
| Second-Look Surgery | 1 | 2019 | 4 | 0.160 |
Why?
|
| Radiation Injuries | 2 | 2018 | 51 | 0.160 |
Why?
|
| Melphalan | 1 | 2019 | 6 | 0.160 |
Why?
|
| Arteriovenous Fistula | 1 | 2019 | 16 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2020 | 98 | 0.160 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2019 | 16 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2019 | 32 | 0.160 |
Why?
|
| Mice | 7 | 2021 | 4478 | 0.160 |
Why?
|
| Gadolinium | 1 | 2019 | 6 | 0.160 |
Why?
|
| Brain | 3 | 2018 | 712 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 107 | 0.160 |
Why?
|
| Adolescent | 3 | 2021 | 2993 | 0.160 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 30 | 0.160 |
Why?
|
| Photons | 1 | 2018 | 27 | 0.150 |
Why?
|
| Cavernous Sinus | 1 | 2018 | 5 | 0.150 |
Why?
|
| Peptides | 2 | 2013 | 283 | 0.150 |
Why?
|
| Brain Diseases | 1 | 2018 | 35 | 0.150 |
Why?
|
| Radio Waves | 1 | 2018 | 21 | 0.150 |
Why?
|
| Electromagnetic Fields | 1 | 2018 | 14 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2013 | 102 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 38 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 19 | 0.150 |
Why?
|
| Proton Therapy | 1 | 2018 | 28 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 22 | 0.150 |
Why?
|
| Hobbies | 1 | 2018 | 1 | 0.150 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 55 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 14 | 0.150 |
Why?
|
| Health Surveys | 1 | 2018 | 78 | 0.150 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 12 | 0.150 |
Why?
|
| Organ Specificity | 1 | 2018 | 81 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 73 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 310 | 0.150 |
Why?
|
| Electric Stimulation Therapy | 1 | 2018 | 56 | 0.150 |
Why?
|
| Infertility, Male | 1 | 2018 | 23 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2021 | 606 | 0.140 |
Why?
|
| Palliative Medicine | 1 | 2017 | 1 | 0.140 |
Why?
|
| Infant | 1 | 2021 | 965 | 0.140 |
Why?
|
| Particle Accelerators | 1 | 2017 | 5 | 0.140 |
Why?
|
| Oregon | 1 | 2017 | 8 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 180 | 0.140 |
Why?
|
| Fertility | 1 | 2018 | 58 | 0.140 |
Why?
|
| Young Adult | 3 | 2019 | 2633 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 39 | 0.140 |
Why?
|
| Bias | 1 | 2017 | 41 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2019 | 143 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 26 | 0.140 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 408 | 0.140 |
Why?
|
| Propensity Score | 1 | 2017 | 54 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2017 | 67 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 52 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2003 | 590 | 0.140 |
Why?
|
| Hemangioblastoma | 1 | 2017 | 12 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 133 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2017 | 230 | 0.130 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 281 | 0.130 |
Why?
|
| DNA Fragmentation | 2 | 2015 | 17 | 0.130 |
Why?
|
| Prostatectomy | 3 | 2017 | 83 | 0.130 |
Why?
|
| DNA, Neoplasm | 2 | 2009 | 33 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2016 | 67 | 0.130 |
Why?
|
| Comorbidity | 1 | 2017 | 250 | 0.130 |
Why?
|
| Sex Factors | 1 | 2018 | 452 | 0.130 |
Why?
|
| Protein Array Analysis | 2 | 2013 | 18 | 0.130 |
Why?
|
| Logistic Models | 1 | 2017 | 398 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 2 | 2009 | 84 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 1944 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 251 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2014 | 278 | 0.120 |
Why?
|
| Cells, Cultured | 3 | 2021 | 978 | 0.120 |
Why?
|
| Heptanoic Acids | 1 | 2015 | 1 | 0.120 |
Why?
|
| Lanosterol | 1 | 2015 | 1 | 0.120 |
Why?
|
| Catechols | 1 | 2015 | 2 | 0.120 |
Why?
|
| Limonins | 1 | 2015 | 2 | 0.120 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 4 | 0.120 |
Why?
|
| Flavones | 1 | 2015 | 3 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 111 | 0.120 |
Why?
|
| Triterpenes | 1 | 2015 | 8 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 68 | 0.120 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 22 | 0.120 |
Why?
|
| Models, Genetic | 2 | 2012 | 123 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 131 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2018 | 1221 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2015 | 285 | 0.110 |
Why?
|
| Transfection | 3 | 2005 | 314 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2018 | 635 | 0.110 |
Why?
|
| Phospholipases A2, Cytosolic | 1 | 2013 | 1 | 0.110 |
Why?
|
| Benzoates | 1 | 2013 | 30 | 0.110 |
Why?
|
| Receptors, Peptide | 1 | 2013 | 20 | 0.100 |
Why?
|
| Peptide Library | 1 | 2013 | 25 | 0.100 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 34 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2013 | 70 | 0.100 |
Why?
|
| Lentivirus | 1 | 2012 | 16 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2003 | 265 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 516 | 0.100 |
Why?
|
| Receptor, trkA | 1 | 2012 | 9 | 0.100 |
Why?
|
| Radiation Tolerance | 1 | 2012 | 28 | 0.100 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2012 | 50 | 0.100 |
Why?
|
| HEK293 Cells | 1 | 2012 | 176 | 0.100 |
Why?
|
| Expert Testimony | 1 | 2011 | 7 | 0.090 |
Why?
|
| Genotype | 2 | 2010 | 444 | 0.090 |
Why?
|
| Unnecessary Procedures | 1 | 2011 | 7 | 0.090 |
Why?
|
| Mastectomy | 1 | 2011 | 21 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 365 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2008 | 76 | 0.090 |
Why?
|
| RNA, Messenger | 1 | 2012 | 648 | 0.090 |
Why?
|
| Phenotype | 1 | 2012 | 668 | 0.090 |
Why?
|
| Cell Death | 2 | 2007 | 111 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2010 | 95 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 466 | 0.080 |
Why?
|
| Hypothyroidism | 1 | 2009 | 11 | 0.080 |
Why?
|
| Thyroid Gland | 1 | 2009 | 31 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2010 | 389 | 0.080 |
Why?
|
| Cell Survival | 3 | 2018 | 396 | 0.080 |
Why?
|
| Phagosomes | 1 | 2009 | 6 | 0.080 |
Why?
|
| Necrosis | 1 | 2009 | 82 | 0.080 |
Why?
|
| Capsid | 1 | 2009 | 12 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 42 | 0.080 |
Why?
|
| Contrast Media | 2 | 2020 | 94 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 68 | 0.080 |
Why?
|
| Bacteriophage T7 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Adenoviridae | 1 | 2009 | 66 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 262 | 0.080 |
Why?
|
| Cloning, Molecular | 1 | 2009 | 205 | 0.080 |
Why?
|
| Caspase Inhibitors | 1 | 2008 | 8 | 0.070 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2009 | 74 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 163 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2009 | 184 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 109 | 0.070 |
Why?
|
| Liposomes | 1 | 2009 | 142 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 455 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 679 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2008 | 241 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 377 | 0.070 |
Why?
|
| Chromones | 2 | 2005 | 11 | 0.070 |
Why?
|
| Morpholines | 2 | 2005 | 27 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 1041 | 0.070 |
Why?
|
| Macrophages | 2 | 2020 | 280 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 236 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2008 | 313 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2002 | 59 | 0.060 |
Why?
|
| Canada | 1 | 2025 | 58 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2005 | 151 | 0.060 |
Why?
|
| Amifostine | 1 | 2004 | 5 | 0.060 |
Why?
|
| Mucous Membrane | 1 | 2004 | 26 | 0.060 |
Why?
|
| Quality of Life | 2 | 2018 | 468 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 140 | 0.060 |
Why?
|
| Algorithms | 2 | 2020 | 422 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 397 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2003 | 47 | 0.050 |
Why?
|
| Vinblastine | 1 | 2002 | 5 | 0.050 |
Why?
|
| Tetracycline | 1 | 2002 | 4 | 0.050 |
Why?
|
| Etoposide | 1 | 2002 | 19 | 0.050 |
Why?
|
| Acetylation | 1 | 2002 | 36 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2022 | 13 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2002 | 74 | 0.050 |
Why?
|
| Histones | 1 | 2002 | 90 | 0.050 |
Why?
|
| Age Factors | 2 | 2018 | 725 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2021 | 8 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2002 | 15 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2002 | 60 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2021 | 36 | 0.050 |
Why?
|
| PubMed | 1 | 2021 | 8 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 331 | 0.050 |
Why?
|
| Time Factors | 2 | 2018 | 1571 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 11 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2020 | 86 | 0.040 |
Why?
|
| Artifacts | 1 | 2020 | 50 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 598 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2019 | 45 | 0.040 |
Why?
|
| Rats | 1 | 2002 | 1554 | 0.040 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 61 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 553 | 0.040 |
Why?
|
| Magnetite Nanoparticles | 1 | 2019 | 15 | 0.040 |
Why?
|
| Preliminary Data | 1 | 2018 | 4 | 0.040 |
Why?
|
| Cell Fusion | 1 | 2018 | 7 | 0.040 |
Why?
|
| Karyotyping | 1 | 2018 | 24 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 2018 | 28 | 0.040 |
Why?
|
| Protons | 1 | 2018 | 54 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2018 | 100 | 0.040 |
Why?
|
| Cell Line | 2 | 2012 | 683 | 0.040 |
Why?
|
| Memantine | 1 | 2018 | 2 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 90 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2018 | 12 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2017 | 2 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2018 | 12 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 52 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 382 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2012 | 568 | 0.040 |
Why?
|
| Risk | 1 | 2017 | 133 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 86 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 113 | 0.040 |
Why?
|
| Length of Stay | 1 | 2018 | 216 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 489 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2018 | 241 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 458 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2018 | 181 | 0.030 |
Why?
|
| Health Promotion | 1 | 2017 | 171 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 1406 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 284 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 40 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 31 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 54 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1498 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2013 | 25 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2013 | 32 | 0.030 |
Why?
|
| Xanthones | 1 | 2012 | 6 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2012 | 53 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 81 | 0.020 |
Why?
|
| Automation | 1 | 2011 | 19 | 0.020 |
Why?
|
| Community Health Services | 1 | 2011 | 32 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2013 | 331 | 0.020 |
Why?
|
| Mammography | 1 | 2011 | 79 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2009 | 18 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 36 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 279 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 201 | 0.020 |
Why?
|
| Everolimus | 1 | 2008 | 16 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2008 | 57 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 143 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 448 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 218 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 153 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 2038 | 0.010 |
Why?
|
| Genes, myc | 1 | 2002 | 9 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2002 | 15 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2002 | 65 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 154 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 150 | 0.010 |
Why?
|